The RSV diagnostics market is experiencing significant growth as global healthcare systems continue to prioritize early and accurate detection of respiratory syncytial virus (RSV) infections, especially among infants, immunocompromised individuals, and the elderly. According to Expert Market Research, the global RSV diagnostics market reached a value of USD 1028.55 million in 2024 and is expected to grow at a CAGR of 10.20% during 2025–2034, reaching USD 2716.70 million by 2034.

RSV Diagnostics Market Size

Respiratory syncytial virus is a leading cause of lower respiratory tract infections in young children and older adults. The rising incidence of RSV globally, coupled with the increasing adoption of point-of-care testing, is significantly boosting the demand for advanced diagnostic technologies.

Healthcare providers are increasingly relying on molecular diagnostics, rapid antigen detection tests (RADTs), and direct fluorescent antibody (DFA) tests for timely RSV detection, thereby reducing hospital admissions and improving patient outcomes. The rapid rise in RSV-related hospitalizations, especially during the seasonal surge months, is further augmenting market expansion.

RSV Diagnostics Market Share

North America currently holds the dominant share in the global RSV diagnostics market, largely due to its robust healthcare infrastructure, high awareness levels, and widespread adoption of early diagnostic screening programs. The United States leads the region, supported by the Centers for Disease Control and Prevention (CDC) guidelines promoting timely RSV diagnosis.

Europe ranks second, driven by increasing RSV burden and favorable reimbursement frameworks. Meanwhile, Asia Pacific is projected to witness the fastest growth due to expanding healthcare access, rising investments in diagnostic laboratories, and increasing awareness in countries like India and China.

Key players dominating the market include Abbott Laboratories, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., and Becton, Dickinson and Company, known for their diversified and innovative diagnostic solutions.

RSV Diagnostics Market Growth & Trends

Several critical factors are driving growth in the RSV diagnostics industry:

  • Rising Global RSV Incidence: RSV is responsible for an estimated 33 million lower respiratory tract infections globally each year, according to Wikipedia, emphasizing the need for early and effective diagnostic solutions.

  • Technological Advancements: The development of highly sensitive molecular diagnostic tools, such as PCR-based assays, is enabling rapid and precise detection of RSV.

  • Increased Demand for Point-of-Care Testing: The shift toward decentralized testing in homecare and clinic settings has led to the widespread adoption of RADTs and immunoassays.

  • Growing Focus on Pediatric and Geriatric Health: RSV poses significant risk to children under five and adults over 65, spurring governments and health organizations to promote early diagnostic protocols.

  • Post-COVID-19 Diagnostic Infrastructure: The global emphasis on infectious disease preparedness post-pandemic has strengthened diagnostic infrastructure, benefiting the RSV testing landscape.

RSV Diagnostics Market Case Studies & News

Recent developments in the market highlight innovation and strategic growth:

  • In 2023, Abbott Laboratories expanded its RSV molecular testing capabilities by integrating RSV detection into its ID NOW™ platform, offering results in under 15 minutes.

  • Roche Diagnostics launched a high-throughput RSV assay for its cobas® 6800/8800 systems, enhancing centralized laboratory testing efficiency.

  • DiaSorin Molecular LLC received FDA clearance for its Simplexa™ Flu A/B & RSV Direct Gen II Kit, which detects and differentiates influenza and RSV simultaneously.

These advancements demonstrate how manufacturers are addressing the need for speed, accuracy, and scalability in RSV diagnostics.

RSV Diagnostics Market Analysis

The competitive landscape is characterized by robust R&D activity, mergers, and the adoption of multiplex testing systems. Companies are investing in diagnostic platforms that offer RSV detection alongside other respiratory pathogens, improving clinical decision-making.

Regulatory factors also play a crucial role, with health authorities emphasizing syndromic testing panels to manage respiratory illness surges. Additionally, reimbursement policies in developed markets are supporting the widespread deployment of advanced RSV diagnostic tools.

Regional Market Dynamics:

  • North America: Advanced diagnostics and government RSV surveillance programs.

  • Europe: Increasing incidence rates and integration of RSV screening in routine diagnostics.

  • Asia Pacific: Emerging economies adopting affordable point-of-care tests.

  • Latin America and MEA: Improving healthcare access and international aid supporting infectious disease diagnostics.

RSV Diagnostics Market Segmentation

By Product Type:

  • Direct Fluorescent Antibody (DFA) Method

  • Rapid Antigen Diagnostic Test (RADT)

  • Molecular Diagnostics

  • Chromatographic Immunoassay

  • Diagnostic Imaging

  • Gel Microdroplets

  • Flow Cytometry

  • Others

By End Use:

  • Hospitals

  • Laboratory

  • Clinics

  • Homecare

By Region:

  • North America

  • Europe

  • Asia Pacific

  • Latin America

  • Middle East and Africa

Molecular diagnostics currently lead the product segment due to their high sensitivity, particularly valuable in detecting RSV in early stages or asymptomatic cases.

RSV Diagnostics Market Key Players

The competitive landscape features a mix of global diagnostic leaders and specialized firms:

  • Abbott Laboratories

  • Thermo Fisher Scientific Inc.

  • F. Hoffmann-La Roche Ltd

  • Becton, Dickinson and Company

  • bioMérieux SA

  • DiaSorin Molecular LLC

  • Others

These companies are expanding their product lines and entering partnerships with public health agencies to meet increasing global demand for RSV testing.

The RSV diagnostics market is poised for strong growth over the next decade, supported by rising infection rates, advances in testing technologies, and a global push for early detection of respiratory illnesses. As health systems expand their diagnostic capabilities, RSV testing will remain a critical component of pediatric and elderly care strategies.

For detailed market forecasts, segment-level analysis, and key trends shaping the industry, access the full report from Expert Market Research.

Find More Report:

CDMO Market trend

Gastric Neuroendocrine Tumors Drug Pipeline Analysis share

Human Immunodeficiency Virus (HIV 1) Infection Drug Pipeline Analysis growth